+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Kidney Cancer Drugs: Global Strategic Business Report

  • PDF Icon

    Report

  • 148 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1882088

Global Kidney Cancer Drugs Market to Reach $8.1 Billion by 2030

The global market for Kidney Cancer Drugs estimated at US$5.6 Billion in the year 2022, is projected to reach a revised size of US$8.1 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2022-2030. Targeted Therapy, one of the segments analyzed in the report, is projected to record 5.1% CAGR and reach US$5.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Immunotherapy segment is readjusted to a revised 4.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 8.2% CAGR

The Kidney Cancer Drugs market in the U.S. is estimated at US$1.5 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Select Competitors (Total 12 Featured) -

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Novartis International AG
  • Pfizer, Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Kidney Cancer Drugs

What is the estimated value of the Global Market for Kidney Cancer Drugs?

The Global Market for Kidney Cancer Drugs was estimated to be valued at $5.6 Billion in 2022.

What is the growth rate of the Global Market for Kidney Cancer Drugs?

The growth rate of the Global Market for Kidney Cancer Drugs is 4.7%, with an estimated value of $8.1 Billion by 2030.

What is the forecasted size of the Global Market for Kidney Cancer Drugs?

The Global Market for Kidney Cancer Drugs is estimated to be worth $8.1 Billion by 2030.

Who are the key companies in the Global Market for Kidney Cancer Drugs?

Key companies in the Global Market for Kidney Cancer Drugs include Bayer AG, Bristol, Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Novartis International AG and Pfizer, Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Kidney Cancer Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Kidney Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 3: World 18-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 6: World 18-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 9: World 18-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 12: World 18-Year Perspective for Angiogenesis Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for mTOR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for mTOR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 15: World 18-Year Perspective for mTOR Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 18: World 18-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Cytokine Immunotherapy (IL-2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 20: World Historic Review for Cytokine Immunotherapy (IL-2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 21: World 18-Year Perspective for Cytokine Immunotherapy (IL-2) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 22: World Kidney Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 24: USA Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 25: USA 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 26: USA Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: USA Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 28: USA 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
CANADA
  • Table 29: Canada Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 31: Canada 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 32: Canada Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: Canada Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 34: Canada 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
JAPAN
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 35: Japan Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 37: Japan 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 38: Japan Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Japan Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 40: Japan 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
CHINA
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 41: China Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: China Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 43: China 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 44: China Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: China Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 46: China 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
EUROPE
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 47: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Kidney Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 49: Europe 18-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 52: Europe 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 53: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 55: Europe 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
FRANCE
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 56: France Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: France Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 58: France 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 59: France Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: France Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 61: France 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
GERMANY
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 62: Germany Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 64: Germany 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 65: Germany Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 66: Germany Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 67: Germany 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
ITALY
  • Table 68: Italy Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 70: Italy 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 71: Italy Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 72: Italy Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 73: Italy 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
UNITED KINGDOM
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 74: UK Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: UK Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 76: UK 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 77: UK Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 78: UK Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 79: UK 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
SPAIN
  • Table 80: Spain Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: Spain Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 82: Spain 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 83: Spain Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 84: Spain Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 85: Spain 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
RUSSIA
  • Table 86: Russia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: Russia Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 88: Russia 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 89: Russia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 90: Russia Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 91: Russia 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
REST OF EUROPE
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 93: Rest of Europe Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 94: Rest of Europe 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 95: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 96: Rest of Europe Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 97: Rest of Europe 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
ASIA-PACIFIC
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Kidney Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 100: Asia-Pacific 18-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 103: Asia-Pacific 18-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2012, 2023 & 2030
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 105: Asia-Pacific Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 106: Asia-Pacific 18-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 & 2030
AUSTRALIA
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Novartis International AG
  • Pfizer, Inc.